| [Table 4.1] |
| |
Note |
2011 |
2012 |
| |
|
€ million |
€ million |
| Net sales |
[7] |
36,528 |
39,760 |
| Cost of goods sold |
|
(17,975) |
(19,059) |
| Gross profit |
|
18,553 |
20,701 |
| |
|
|
|
| Selling expenses |
[8] |
(8,958) |
(9,987) |
| Research and development expenses |
[9] |
(2,932) |
(3,013) |
| General administration expenses |
|
(1,713) |
(1,866) |
| Other operating income |
[10] |
859 |
1,083 |
| Other operating expenses |
[11] |
(1,660) |
(2,958) |
| EBIT* |
|
4,149 |
3,960 |
| |
|
|
|
| Equity-method loss |
[13.1] |
(45) |
(46) |
| Financial income |
|
586 |
502 |
| Financial expenses |
|
(1,327) |
(1,168) |
| Financial result |
[13] |
(786) |
(712) |
| |
|
|
|
| Income before income taxes |
|
3,363 |
3,248 |
| |
|
|
|
| Income taxes |
[14] |
(891) |
(752) |
| |
|
|
|
| Income after taxes |
|
2,472 |
2,496 |
| of which attributable to non-controlling interest |
[15] |
2 |
50 |
of which attributable to Bayer AG stockholders
(net income) |
|
2,470 |
2,446 |
| |
|
|
|
| |
|
€ |
€ |
| Earnings per share |
[16] |
|
|
| Basic |
|
2.99 |
2.96 |
| Diluted |
|
2.99 |
2.96 |
| * EBIT: Earnings before financial result and taxes |
